List of Excipients in Branded Drug INFUVITE PEDIATRIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	INFUVITE PEDIATRIC	multiple vitamins injection	54643-5646	ANHYDROUS CITRIC ACID
Sandoz Inc	INFUVITE PEDIATRIC	multiple vitamins injection	54643-5646	HYDROCHLORIC ACID
Sandoz Inc	INFUVITE PEDIATRIC	multiple vitamins injection	54643-5646	MANNITOL
Sandoz Inc	INFUVITE PEDIATRIC	multiple vitamins injection	54643-5646	POLYSORBATE 80
Sandoz Inc	INFUVITE PEDIATRIC	multiple vitamins injection	54643-5646	SODIUM CITRATE
Sandoz Inc	INFUVITE PEDIATRIC	multiple vitamins injection	54643-5646	SODIUM HYDROXIDE

Infuvite Pediatric Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 2, 2026

Infuvite Pediatric is an intravenous multivitamin product used as a component of parenteral nutrition for infants and children. Its commercial value is driven less by novel active-ingredient exclusivity and more by formulation reliability, compatibility with parenteral nutrition, neonatal safety, packaging, supply continuity, and hospital procurement economics. The product appears to have limited current patent protection in the FDA Orange Book, leaving formulation, manufacturing, regulatory, and trade-secret barriers as the main routes to differentiation.

Key findings

• Infuvite Pediatric uses a two-vial system to separate vitamins with different stability and solubility requirements.
• The excipient platform relies on solubilization, pH control, and aqueous injectable manufacturing rather than a complex delivery technology.
• The main commercial opportunities are ready-to-use presentations, improved stability after admixture, reduced preparation steps, preservative-free supply, neonatal-use positioning, and pharmacy workflow improvements.
• No biologic exclusivity or biosimilar pathway applies.
• A conventional generic could potentially pursue an abbreviated pathway if it matches the reference product’s active ingredients, dosage form, strength, route, labeling, and quality attributes.
• The principal risks are formulation equivalence, vitamin degradation, container interaction, particulate control, sterilization, and compatibility with parenteral nutrition admixtures.

What is Infuvite Pediatric and how is it used?

Infuvite Pediatric is a multiple-vitamin injection for intravenous administration after dilution. It supplies vitamins for pediatric patients receiving parenteral nutrition when oral or enteral administration is inadequate or impossible. The FDA labeling covers pediatric patients, with dosing determined by age and clinical condition.[1]

The product is supplied as two sterile components:

Component	Principal function
Vial 1	Contains water-soluble vitamins and fat-soluble vitamins A, D, and E
Vial 2	Contains vitamin K
Final administration	Components are combined and diluted before intravenous use

The labeled pediatric dose includes vitamin A, vitamin D, vitamin E, vitamin C, thiamine, riboflavin, niacinamide, pyridoxine, folic acid, vitamin B12, biotin, pantothenic acid, and vitamin K.[1]

The two-vial architecture is commercially important. Vitamin K and other ingredients may have different stability, solubility, and interaction profiles from the ingredients placed in Vial 1. Separate packaging permits the manufacturer to control the formulation environment for each component and combine the contents shortly before use.

What excipients are used in Infuvite Pediatric?

The FDA labeling identifies excipients that support solubility, formulation control, and injectable product manufacture. The listed inactive ingredients include polysorbate 80, glycerin, propylene glycol, hydrochloric acid, sodium hydroxide, and water for injection, although the distribution of excipients between the two vials should be evaluated against the current approved package insert.[1]

Excipient or formulation element	Likely technical role	Commercial relevance
Polysorbate 80	Solubilization and dispersion of poorly water-soluble vitamins	Can create opportunities in surfactant selection, oxidation control, and container compatibility
Glycerin	Solvent and tonicity contribution	May affect osmolality, viscosity, and tolerability
Propylene glycol	Co-solvent for poorly water-soluble components	Creates opportunities for alternative solvent systems and pediatric tolerability positioning
Hydrochloric acid and sodium hydroxide	pH adjustment	Critical to vitamin stability and injectable compatibility
Water for injection	Primary vehicle	Requires control of endotoxin, conductivity, particulates, and microbial quality

The formulation is not a simple aqueous vitamin solution. Vitamins A, D, E, and K have limited water solubility and are vulnerable to degradation from light, oxygen, pH shifts, and adsorption. Water-soluble vitamins also have different degradation pathways. The excipient system therefore has to balance solubility with chemical stability, low particulate burden, acceptable osmolality, and compatibility with intravenous administration.

Why does Infuvite Pediatric use a two-vial formulation?

The two-vial configuration reduces the need to maintain every vitamin in one chemically optimized environment throughout shelf life. It also permits separate control of vitamin K and reduces the risk that a single formulation change will destabilize the complete vitamin blend.

For a competitor, the two-vial structure creates both a barrier and an opportunity. A single-vial product could offer pharmacy convenience, but it would require evidence that all vitamins remain within specification through the proposed shelf life and after dilution. The sponsor would also need to address precipitation, degradation products, pH, particulate matter, and compatibility with parenteral nutrition solutions.

A competitor could instead retain the two-vial structure and compete on:

• Faster reconstitution.
• Reduced vial overfill and waste.
• Clearer labeling.
• Lower extractables and leachables risk.
• Improved protection from light and oxygen.
• More convenient pharmacy packaging.
• Better post-reconstitution stability data.

What excipient strategies could improve the product?

Can a competitor replace polysorbate 80?

A competitor could evaluate alternative surfactants or solubilizers, but replacement would not be a routine substitution. The change would affect vitamin solubility, emulsion or dispersion behavior, degradation, container interaction, and local tolerability.

Potential alternatives include other nonionic surfactants, cyclodextrin-based solubilization, modified solvent systems, or redesigned vitamin intermediates. Each approach would require a full injectable development program. The strongest opportunity is not simply to remove polysorbate 80, but to show a measurable clinical or operational advantage, such as:

• Lower peroxide-related degradation.
• Lower risk of visible or subvisible particles.
• Reduced adsorption to infusion components.
• Improved stability in common parenteral nutrition admixtures.
• Lower risk of hypersensitivity concerns associated with certain excipient classes.

A surfactant-free formulation would be commercially differentiated only if it retains adequate solubility and shelf life without increasing preparation complexity.

Can propylene glycol be reduced or eliminated?

Propylene glycol is used as a co-solvent in many injectable formulations. A reduced- or no-propylene-glycol formulation could be positioned for neonatal and pediatric use, but the commercial claim would require careful regulatory and clinical support.

The development target would be an alternative solvent system that maintains:

• Vitamin solubility.
• Chemical stability.
• Acceptable osmolality.
• Low injection-site and systemic tolerability risk.
• Compatibility with parenteral nutrition admixtures.

This strategy may have more value in neonatal intensive care settings, where excipient exposure is closely scrutinized. The commercial benefit would be strongest if supported by comparative toxicology, validated impurity control, and clear dosing guidance.

Can pH and buffering be redesigned?

The formulation uses acid and base for pH adjustment rather than a prominent buffer system. This approach can reduce buffer load and limit interactions with parenteral nutrition solutions. A competitor could investigate a buffered system, but buffer selection may affect vitamin degradation and compatibility.

A lower-buffer formulation may be advantageous because the final product is often diluted into a larger nutrition solution. Excess buffering could shift the pH of the admixture or affect the stability of other nutrients. The most defensible product attribute would be demonstrated post-admixture stability under clinically relevant storage and administration conditions.

What formulations are protected by Infuvite Pediatric?

The commercially relevant formulation characteristics include the vitamin combination, two-vial presentation, excipient system, concentration, pH range, sterile aqueous vehicle, and instructions for dilution. The product’s protection is more likely to arise from regulatory approval, manufacturing know-how, and formulation trade secrets than from a broad, enforceable patent estate.

A patent search should distinguish among:

1. Patents covering the vitamin combination.
2. Patents covering the two-vial configuration.
3. Patents covering solubilization or stabilization.
4. Patents covering containers, closures, or light protection.
5. Patents covering parenteral nutrition admixture use.
6. Patents covering manufacturing and sterilization controls.

No current FDA Orange Book patent listing was identified for Infuvite Pediatric in the product information reviewed.[2] That finding indicates that an applicant should not assume a listed-patent barrier or automatic Paragraph IV litigation risk. It does not eliminate the possibility of unlisted patents, expired patents, foreign rights, process patents, or contractual restrictions.

When does Infuvite Pediatric lose exclusivity?

Infuvite Pediatric is an established injectable product rather than a newly launched small-molecule product with a prominent modern exclusivity timeline. The commercial exclusivity analysis therefore depends on the current approved application, any listed patents, regulatory exclusivity, and market authorization status.

Exclusivity category	Infuvite Pediatric assessment
New chemical entity exclusivity	Not applicable to this established multivitamin combination
Biologic exclusivity	Not applicable
Biosimilar pathway	Not applicable
Pediatric exclusivity	No current six-month pediatric extension was identified in the reviewed product materials
Orange Book listed patents	No current listing identified in the reviewed Orange Book record
Generic competition	Potentially available through an abbreviated or other FDA pathway, subject to product-specific requirements
Formulation and manufacturing know-how	Potentially material even without active patents

For a competing applicant, the absence of an Orange Book patent listing can shorten the legal path to market. The main delay is more likely to arise from formulation development, injectable quality requirements, FDA review, manufacturing readiness, and supply-chain validation.

What is the Orange Book status of Infuvite Pediatric?

The Orange Book provides patent and exclusivity information for eligible FDA-approved drug products.[2] Infuvite Pediatric does not appear to have a current listed patent barrier in the record reviewed.

The practical implications are:

• A Paragraph IV certification may not be required if no relevant patent is listed.
• A generic applicant still must address the reference product’s active and inactive ingredients, dosage form, strength, route, sterility, labeling, and quality attributes.
• A product with a different excipient system may require a different regulatory strategy.
• A material formulation change could create a 505(b)(2) pathway rather than a straightforward ANDA pathway, depending on the proposed product and the extent of reliance on the reference product.[3]

Which companies are challenging Infuvite Pediatric?

No active public Paragraph IV challenge or patent litigation involving Infuvite Pediatric was identified in the reviewed FDA and publicly available patent records. The competitive field is more likely to involve manufacturers of generic multiple-vitamin injections, hospital suppliers, compounding pharmacies, and parenteral nutrition providers.

The relevant competitors fall into four groups:

Competitor group	Competitive basis
Generic multiple-vitamin injection manufacturers	Lower acquisition cost and existing hospital contracts
Parenteral nutrition suppliers	Bundled nutrition services and integrated pharmacy supply
Outsourcing facilities	Ready-to-administer or customized compounded presentations
New formulation developers	Reduced preparation, improved stability, or differentiated excipients

The competitive risk is operational rather than litigation-led. Hospitals may switch suppliers when a product is unavailable, requires fewer preparation steps, has more favorable stability data, or reduces pharmacy labor.

What commercial opportunities exist for an Infuvite Pediatric competitor?

Ready-to-use or pharmacy-efficient packaging

A ready-to-use presentation could reduce manipulation in hospital pharmacies. Potential formats include:

• Dual-chamber containers.
• Pre-mixed pharmacy bags.
• Unit-dose kits.
• Larger institutional packs.
• Barcode-enabled cartons.
• Tamper-evident kits with integrated transfer devices.

The regulatory and stability burden would increase with each format change. A dual-chamber container may preserve the chemical separation of the existing two-vial system while reducing manual transfers.

Improved post-admixture stability

Post-admixture stability is a high-value differentiator. The product is commonly used in parenteral nutrition, where vitamins encounter amino acids, dextrose, electrolytes, trace elements, lipids, tubing, and container materials.

A competing product could generate value by demonstrating:

• Longer stability after dilution.
• Compatibility with total nutrient admixtures.
• Lower vitamin loss during storage.
• Reduced light sensitivity.
• Lower adsorption to bags and tubing.
• Acceptable stability under refrigerated and room-temperature conditions.

The evidence would need to cover chemical potency, degradation products, sterility, endotoxins, visible particles, subvisible particles, and container integrity.

Neonatal and pediatric excipient positioning

Pediatric hospitals may value a formulation with lower excipient exposure, reduced preparation volume, or more predictable dosing. Relevant development concepts include:

• Lower propylene glycol exposure.
• Reduced surfactant load.
• Lower final volume.
• Reduced osmolality contribution.
• Clearer age- and weight-based dosing.
• Improved compatibility with neonatal nutrition regimens.

These attributes can support premium pricing only if they reduce pharmacy workload, clinical concern, waste, or adverse-event monitoring.

Supply continuity and shortage resilience

Parenteral nutrition products are vulnerable to manufacturing interruptions because sterile injectable production has limited qualified capacity. A new supplier could compete through:

• Dual manufacturing sites.
• Regional safety stock.
• Redundant active pharmaceutical ingredient suppliers.
• Domestic fill-finish capacity.
• Shorter lead times.
• Transparent allocation policies.

FDA drug shortage information and hospital purchasing data should be monitored for recurring supply interruptions affecting multiple-vitamin injections.[4] A reliable supplier may win contracts even without a lower unit price.

How strong is the patent estate for Infuvite Pediatric?

The patent estate appears weak as a current market-exclusion mechanism and stronger as a historical or know-how-based protection system.

Patent-strength factor	Assessment
Active ingredient patents	Effectively unavailable for the mature vitamin ingredients
New-combination patent value	Limited by long commercial history and prior art
Excipient formulation patents	Possible, but validity and scope would require claim-level review
Device or packaging patents	Potentially more relevant for new dual-chamber or ready-to-use systems
Process patents	Potentially useful but difficult to enforce against independently developed processes
Trade secrets	Likely important for stability controls, compounding order, sterilization, and impurity management
Orange Book leverage	No current listed-patent barrier identified

The strongest defensible position for a new entrant would likely combine a differentiated presentation, validated stability package, manufacturing know-how, and hospital contracts. A composition-of-matter patent strategy for the basic vitamin blend would have limited prospects.

What generic launch risks exist?

A generic launch would face five principal risks.

Pharmaceutical equivalence

The applicant would need to match the reference product’s active ingredients, dosage form, strength, route, and quality requirements. The two-vial presentation and vitamin concentration profile may complicate equivalence assessment.

Injectable product quality

Sterility, endotoxins, particulate matter, container closure integrity, and aseptic processing create higher development and inspection risk than an oral tablet.

Vitamin degradation

The formulation must control oxidation, hydrolysis, photodegradation, and interaction among vitamins. Stability failures can occur even when the initial assay is acceptable.

Admixture compatibility

The product must perform predictably after dilution into parenteral nutrition solutions. Differences in bags, tubing, filters, lipids, trace elements, and storage conditions can affect the result.

Commercial scale

The market is institutionally concentrated. Hospital contracts, group purchasing organizations, and pharmacy formularies can limit uptake even when regulatory approval is obtained.

What FDA regulatory pathway would apply to a new product?

A close duplicate may be suitable for an ANDA if the applicant can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements for the product class.[3] A product with a materially different excipient system, presentation, concentration, or labeling may require a 505(b)(2) application.

The likely pathway depends on:

• Whether the proposed product is pharmaceutically equivalent.
• Whether the reference product is eligible for ANDA comparison.
• Whether the applicant relies on FDA findings for the reference product.
• Whether the excipient differences raise safety or clinical questions.
• Whether the product is a combination of separately packaged components.
• Whether the proposed labeling differs from the reference labeling.

The product is not eligible for the biosimilar pathway because it is not a biologic product under the Public Health Service Act.[5]

What manufacturing and intellectual-property barriers matter most?

The key manufacturing barriers are:

• Controlled dissolution of poorly water-soluble vitamins.
• Oxygen and light management.
• Low-bioburden and aseptic processing.
• Sterilization validation.
• Control of vitamin degradation products.
• Accurate low-dose filling for vitamins and micronutrients.
• Container closure integrity.
• Compatibility with transfer devices and infusion equipment.

The most valuable know-how may involve the order of ingredient addition, temperature control, pH adjustment, nitrogen overlay, hold times, filtration, and packaging conditions. Those controls can be difficult to identify through reverse engineering and may remain protectable as trade secrets.

Geographic protection is likely to be stronger through manufacturing and distribution control than through pharmaceutical patent coverage. A supplier with U.S. sterile manufacturing and regional distribution can use service levels and shortage resilience as commercial barriers, while foreign markets may apply different rules for pediatric multivitamin injections and parenteral nutrition products.

How does Infuvite Pediatric compare with alternative multivitamin injections?

Attribute	Infuvite Pediatric	New generic duplicate	Differentiated reformulation
Regulatory risk	Existing approved product	Moderate to high	Higher
Excipient flexibility	Fixed by approved labeling	Limited if pursuing ANDA	Greater under 505(b)(2)
Patent risk	No current listed patent barrier identified	Low Orange Book risk	Depends on new claims
Pharmacy convenience	Two-vial preparation	Similar unless redesigned	Potentially superior
Stability opportunity	Existing benchmark	Must match or exceed	Major differentiation route
Pricing position	Reference or contract price	Discounted	Premium if workflow or safety value is demonstrated
Biosimilar relevance	None	None	None

Key Takeaways

Infuvite Pediatric is an established pediatric intravenous multivitamin product whose competitive position rests on formulation performance and supply reliability rather than modern active-ingredient patent exclusivity.

The two-vial design is the central formulation feature. It manages vitamin stability but creates an opportunity for competitors to develop dual-chamber, ready-to-use, or lower-waste presentations.

The most credible excipient opportunities are reduced propylene glycol exposure, alternative solubilization, lower surfactant burden, improved oxidation control, and better post-admixture stability. Each change would require injectable quality and compatibility evidence.

No current Orange Book patent barrier or public Paragraph IV challenge was identified in the reviewed records. Biosimilar competition is irrelevant because Infuvite Pediatric is not a biologic.

The strongest commercial strategy is a product that reduces pharmacy preparation, improves stability in parenteral nutrition, maintains pediatric tolerability, and provides reliable supply. The strongest IP strategy is likely to focus on formulation improvements, packaging, manufacturing processes, and trade secrets rather than the mature vitamin combination itself.

FAQs

Is Infuvite Pediatric preservative-free?

The product is labeled as a sterile injectable formulation and is not presented as a conventional multidose preserved product. The current package insert should control the assessment of preservatives and vial-use instructions.[1]

Can Infuvite Pediatric be added to lipid emulsions?

Compatibility depends on the specific parenteral nutrition formulation, lipid system, container, storage period, and administration conditions. The product should be evaluated under validated admixture protocols rather than assumed compatible across all lipid emulsions.

Could a company patent a new Infuvite Pediatric substitute?

A company could pursue patents covering a new excipient system, stability profile, container, dual-chamber presentation, manufacturing process, or admixture method. The claims would need to distinguish the product from the extensive prior art surrounding injectable multivitamins and parenteral nutrition.

Would a lower-volume pediatric multivitamin have commercial value?

Yes. Lower volume can reduce infusion burden and improve pharmacy handling, but the product would need to preserve dose accuracy, solubility, stability, osmolality, and compatibility with pediatric nutrition regimens.

Is Infuvite Pediatric subject to a six-month pediatric exclusivity extension?

No current six-month pediatric exclusivity extension was identified in the reviewed FDA product and Orange Book materials. The commercial analysis should focus on current patents, application status, and regulatory pathway rather than assuming pediatric exclusivity.

References

1. U.S. Food and Drug Administration. (n.d.). Infuvite Pediatric: Multiple vitamins injection prescribing information. FDA-approved product labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

3. U.S. Food and Drug Administration. (2019). ANDA submissions: Refuse-to-receive standards guidance for industry. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (n.d.). Drug shortages. FDA Drug Shortages Database.

5. U.S. Food and Drug Administration. (2015). Biosimilars basics. Center for Drug Evaluation and Research.